One of the pioneers in biotechnology, Biogen today has the leading portfolio of medicines to treat multiple sclerosis (MS), has the first and only approved treatment for spinal muscular atrophy (SMA) and is at the forefront of research into new medicines for neurological and neurodegenerative conditions. Biogen uses novel science and leading-edge technologies to create, commercialize, and manufacture therapies for patients with few or no treatment options.
We are applying our expertise to solve some of the most challenging and complex diseases in neurology, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).
Biogen truly is a global organization, headquartered in Cambridge, Massachusetts. Our international headquarters are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. Our manufacturing skills and focuses enable us to manufacture and supply medicines to patients in more than 90 countries.